Post-Transplant Cyclophosphamide and Sirolimus based Graft-versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative option for many patients with high-risk hematological malignancies.1, 2 Although the outcome of allogeneic HSCT has dramatically improved over the past decade and despite its therapeutic potential,3 toxicities following its application and transplant-related mortality (TRM) still limit its use.

Source: Biology of Blood and Marrow Transplantation - May 31, 2021 Category: Hematology Authors: Raffaella Greco, Francesca Lorentino, Serena Albanese, Maria Teresa Lupo Stanghellini, Fabio Giglio, Simona Piemontese, Daniela Clerici, Lorenzo Lazzari, Magda Marcatti, Sara Mastaglio, Elisabetta Xue, Francesca Farina, Francesca Pavesi, Andrea Assanelli, Source Type: research